Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tipifarnib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA known ✓ | P49354 | 15/20 | 0.80 |
| ▸ | FNTB known ✓ | P49356 | 15/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.76 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tipifarnib SCHEMBL22772860 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL30436988 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL94807 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL29371885 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL29352433 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL23633189 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| (S)-Tipifarnib SCHEMBL4429738 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL21544535 | 1.00 | FNTA (0.80) | FNTAFNTBCYP3A4PGGT1B | |
| Tipifarnib SCHEMBL22468601 | 0.96 | FNTA (0.74) | FNTAFNTBCYP3A4PGGT1B | |
| SCHEMBL12021666 | 0.95 | FNTA (0.72) | FNTAFNTBCYP3A4PGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16520 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12626784-B2 | Colorectal cancer consensus molecular subtype classifier codesets and methods of use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-12 | — | — | US | claimed |
| EP-4721758-A1 | NOVEL MEDICINE FOR TREATING OSTEOSARCOMA | Japanese Foundation For Cancer Research (JP) | 2026-04-08 | — | — | EP | claimed |
| EP-4719410-A1 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF KRAS-DEPENDENT CANCERS | Kura Oncology, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-3781713-B1 | SYSTEMS AND METHODS FOR DETECTING CANCER VIA CFDNA SCREENING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-03-18 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-12544360-B2 | Pharmaceutical composition for preventing or treating coronavirus disease-19 | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-02-10 | — | — | US | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12527781-B2 | Treatment of neurodegenerative conditions by disruption of Rhes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | claimed |
| US-20040102452-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-05-27 | — | — | US | claimed |
| US-20040097516-A1 | Novel pyrazolopyridines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2004-05-20 | — | — | US | claimed |
| WO-2004026229-A2 | PYRAZOLO[1,5-A]PYRIMIDINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-04-01 | — | — | WO | claimed |
| WO-2004022559-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| WO-2004022062-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-03-18 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-1094839-B1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH (IN VIVO) RADIOSENSITIZING PROPERTIES | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-02 | — | — | EP | claimed |
| US-6545020-B1 | (Imidazoly-5-yl)methyl-2-quinolinone derivatives for administration before, during or after irradiation of a tumor for treating cancer in vivo. | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-04-08 | — | — | US | claimed |
| EP-1094839-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH $i(IN VIVO) RADIOSENSITIZING PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-02 | — | — | EP | claimed |
| WO-2000001411-A1 | FARNESYL PROTEIN TRANSFERASE INHIBITORS WITH IN VIVO RADIOSENSITIZING PROPERTIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-01-13 | — | — | WO | claimed |